发布求助
文献互助 智能选刊 最新文献

Immuno-oncology technology最新文献

筛选
英文 中文
99P Real-world management of ir-colitis: A Danish 10-year cohort study
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100842
S.K. Petersen , S. Madley , J. Kjeldsen , L. Bastholt , C.H. Ruhlmann
{"title":"99P Real-world management of ir-colitis: A Danish 10-year cohort study","authors":"S.K. Petersen , S. Madley , J. Kjeldsen , L. Bastholt , C.H. Ruhlmann","doi":"10.1016/j.iotech.2024.100842","DOIUrl":"10.1016/j.iotech.2024.100842","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100842"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma 转移性粘膜黑色素瘤患者在肿瘤浸润淋巴细胞和溶瘤腺病毒（TILT-123）联合治疗后的持久完全缓解。
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100726
T.J. Monberg , T. Kudling , B. Albieri , S. Pakola , E. Ellebaek , M. Donia , R.L. Eefsen , C. von Buchwald , C. Kistler , J.M. Santos , J. Clubb , L. Haybout , M.C.W. Westergaard , D.C.A. Quixabeira , E. Jirovec , R. Havunen , S. Sorsa , V. Cervera-Carrascon , A. Hemminki , I.M. Svane
{"title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","authors":"T.J. Monberg ,&nbsp;T. Kudling ,&nbsp;B. Albieri ,&nbsp;S. Pakola ,&nbsp;E. Ellebaek ,&nbsp;M. Donia ,&nbsp;R.L. Eefsen ,&nbsp;C. von Buchwald ,&nbsp;C. Kistler ,&nbsp;J.M. Santos ,&nbsp;J. Clubb ,&nbsp;L. Haybout ,&nbsp;M.C.W. Westergaard ,&nbsp;D.C.A. Quixabeira ,&nbsp;E. Jirovec ,&nbsp;R. Havunen ,&nbsp;S. Sorsa ,&nbsp;V. Cervera-Carrascon ,&nbsp;A. Hemminki ,&nbsp;I.M. Svane","doi":"10.1016/j.iotech.2024.100726","DOIUrl":"10.1016/j.iotech.2024.100726","url":null,"abstract":"<div><h3>Background</h3><div>Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other.</div></div><div><h3>Patient and methods</h3><div>We present a case of a 48-year-old woman with metastatic sinonasal mucosal melanoma who achieved a durable complete pathological response following treatment with multiple injections of the oncolytic virus TILT-123 (igrelimogene litadenorepvec) and a single infusion of TILs, without preconditioning chemotherapy or postconditioning interleukin-2.</div></div><div><h3>Results</h3><div>Immunohistochemical analysis and single-cell sequencing revealed interesting alterations in injected and noninjected tumors as well as in peripheral blood, during the treatment course, suggesting that TILT-123 facilitated TIL engraftment into the tumor, ultimately leading to a complete response.</div></div><div><h3>Conclusions</h3><div>This case underscores the potential of combined immunotherapeutic approaches as a promising strategy for patients with metastatic mucosal melanoma.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
10P Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100893
I.A. Laklouk
{"title":"10P Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome","authors":"I.A. Laklouk","doi":"10.1016/j.iotech.2024.100893","DOIUrl":"10.1016/j.iotech.2024.100893","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100893"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
53P Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100864
S. Srivastava, M. Mangolini, E. Souster, K. Hu, D. Pombal, L. Schultz, Y. Yang, B. Ma, S. Cordoba, S. Onuoha
{"title":"53P Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma","authors":"S. Srivastava,&nbsp;M. Mangolini,&nbsp;E. Souster,&nbsp;K. Hu,&nbsp;D. Pombal,&nbsp;L. Schultz,&nbsp;Y. Yang,&nbsp;B. Ma,&nbsp;S. Cordoba,&nbsp;S. Onuoha","doi":"10.1016/j.iotech.2024.100864","DOIUrl":"10.1016/j.iotech.2024.100864","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100864"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143130226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
57P SENDER™ directed LNP delivery of mRNA for in situ generation of highly potent CAR T cells
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100868
B. Ma, K. Hu, R. Karatill, R. Williams, J. Hayre, S. Srivastava, S. Cordoba, S. Onuoha
{"title":"57P SENDER™ directed LNP delivery of mRNA for in situ generation of highly potent CAR T cells","authors":"B. Ma,&nbsp;K. Hu,&nbsp;R. Karatill,&nbsp;R. Williams,&nbsp;J. Hayre,&nbsp;S. Srivastava,&nbsp;S. Cordoba,&nbsp;S. Onuoha","doi":"10.1016/j.iotech.2024.100868","DOIUrl":"10.1016/j.iotech.2024.100868","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100868"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143134576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
33P Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100915
J. Mathiot , B. Ndao , L. Boullerot , A. Marguier , C. Laheurte , O. Adotevi , F. Aubin , C. Nardin
{"title":"33P Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors","authors":"J. Mathiot ,&nbsp;B. Ndao ,&nbsp;L. Boullerot ,&nbsp;A. Marguier ,&nbsp;C. Laheurte ,&nbsp;O. Adotevi ,&nbsp;F. Aubin ,&nbsp;C. Nardin","doi":"10.1016/j.iotech.2024.100915","DOIUrl":"10.1016/j.iotech.2024.100915","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100915"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100837
D. Ziogas , H. Linardou , A. Charpidou , A. Koumarianou , G. Mountzios , P. Kosmidis , C. Christodoulou , D. Mavroudis , A.N. Christopoulou , I. Korantzis , S. Baka , M. Vaslamatzis , I. Athanasiadis , A. Koutras , D. Mauri , A. Kotsakis , A. Visvikis , F. Spanoudi , T. Tsichritzis , K. Syrigos
{"title":"94P Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first-line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study","authors":"D. Ziogas ,&nbsp;H. Linardou ,&nbsp;A. Charpidou ,&nbsp;A. Koumarianou ,&nbsp;G. Mountzios ,&nbsp;P. Kosmidis ,&nbsp;C. Christodoulou ,&nbsp;D. Mavroudis ,&nbsp;A.N. Christopoulou ,&nbsp;I. Korantzis ,&nbsp;S. Baka ,&nbsp;M. Vaslamatzis ,&nbsp;I. Athanasiadis ,&nbsp;A. Koutras ,&nbsp;D. Mauri ,&nbsp;A. Kotsakis ,&nbsp;A. Visvikis ,&nbsp;F. Spanoudi ,&nbsp;T. Tsichritzis ,&nbsp;K. Syrigos","doi":"10.1016/j.iotech.2024.100837","DOIUrl":"10.1016/j.iotech.2024.100837","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100837"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
86P Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100829
V. Nurmela , O. Kuittinen , S. Pasonen-Seppänen , A. Juntunen , S.K. Tiainen , A. Rönkä
{"title":"86P Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients","authors":"V. Nurmela ,&nbsp;O. Kuittinen ,&nbsp;S. Pasonen-Seppänen ,&nbsp;A. Juntunen ,&nbsp;S.K. Tiainen ,&nbsp;A. Rönkä","doi":"10.1016/j.iotech.2024.100829","DOIUrl":"10.1016/j.iotech.2024.100829","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100829"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
12P Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100895
E.Y. Baitei , A. Bzura , M. Zhang , C. Poile , A. Branson , A. King , S. Barber , C. Brookes , J. Dzialo , A. Greystoke , L. Nolan , M. Dungey , M. Scotland , A. Bajaj , P. Wells-Jordan , C. Richards , A. Thomas , M.G. Krebs , D.A. Fennell
{"title":"12P Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma","authors":"E.Y. Baitei ,&nbsp;A. Bzura ,&nbsp;M. Zhang ,&nbsp;C. Poile ,&nbsp;A. Branson ,&nbsp;A. King ,&nbsp;S. Barber ,&nbsp;C. Brookes ,&nbsp;J. Dzialo ,&nbsp;A. Greystoke ,&nbsp;L. Nolan ,&nbsp;M. Dungey ,&nbsp;M. Scotland ,&nbsp;A. Bajaj ,&nbsp;P. Wells-Jordan ,&nbsp;C. Richards ,&nbsp;A. Thomas ,&nbsp;M.G. Krebs ,&nbsp;D.A. Fennell","doi":"10.1016/j.iotech.2024.100895","DOIUrl":"10.1016/j.iotech.2024.100895","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100895"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143175730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
19P Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100902
B.V. Popescu , N. Taris , A. Bendjama , L. Bender , C. Pflumio , C. Fischbach , M. Kalish-Weindling , C. Mathelin , T. Petit , X. Pivot
{"title":"19P Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab","authors":"B.V. Popescu ,&nbsp;N. Taris ,&nbsp;A. Bendjama ,&nbsp;L. Bender ,&nbsp;C. Pflumio ,&nbsp;C. Fischbach ,&nbsp;M. Kalish-Weindling ,&nbsp;C. Mathelin ,&nbsp;T. Petit ,&nbsp;X. Pivot","doi":"10.1016/j.iotech.2024.100902","DOIUrl":"10.1016/j.iotech.2024.100902","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100902"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信